MMED on Nasdaq

MiniMed Group, Inc.

American surgical and medical instruments and apparatus company. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

$3.1BRevenue, fiscal 2026³

-$333.0MNet income, fiscal 2026³

Compare with West Pharmaceutical Services (United States), Globus Medical or Insulet (United States), or pick any stock.

TickerMMED on Nasdaq²
IndustrySurgical & Medical Instruments & Apparatus²
HeadquartersWilmington, United States²
Incorporated inDE⁴
Business address18000 Devonshire St., Northridge, Ca 91325⁴
Filer categoryNon-accelerated filer⁴
Legal formCorporation²
LEI254900MS5BIVZH51VD96²
StatusActive²
LEI statusIssued and current²
Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States²
Registered withDivision of Corporations, Department of State, 10113270²

See how the biggest companies compare on our leaderboards

The Company cautions investors that such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.⁵ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

54.2%Gross margin³

-6.1%Operating margin³

-10.7%Net margin³

14.3%Revenue growth, 2026³

-9.2%Return on equity³

-$420.0MFree cash flow³

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Continuous Glucose Monitoring Systems (CGM) brought in 50% of the revenue MiniMed Group, Inc. broke down this way in fiscal 2026.

Continuous Glucose Monitoring Systems (CGM)$1.6B³50%up 18% from 2025
Consumables$956.0M³31%up 12% from 2025
Pumps$546.0M³18%up 1% from 2025
Product and Service, Other$46.0M³1%up 667% from 2025

Products and services by year

Products and services	2024	2025	2026
Continuous Glucose Monitoring Systems (CGM)	$1.1B	$1.3B	$1.6B
Consumables	$777.0M	$854.0M	$956.0M
Pumps	$540.0M	$541.0M	$546.0M
Product and Service, Other	$34.0M	$6.0M	$46.0M

Regions

Outside the United States brought in 70% of the revenue MiniMed Group, Inc. broke down this way in fiscal 2026.

Outside the United States$2.2B³70%up 21% from 2025
United States$917.0M³30%up 2% from 2025

Regions by year

Regions	2024	2025	2026
Outside the United States	$1.6B	$1.8B	$2.2B
United States	$833.0M	$903.0M	$917.0M

Where the money goes

Where each dollar of revenue went, fiscal 2026

Cost of revenueSelling, general and adminOther costs

Cost of revenue46¢$1.4B
Selling, general and admin38¢$1.2B
Other costs12¢$369.0M
Income tax4¢$128.0M

Out of $3.1B in revenue.³ The company lost money this year.

Financial statements

Revenue³$3.1B in 2026+26% since 2024

Gross profit³$1.7B in 2026+17% since 2024

Operating income³-$190.0M in 2026+175% since 2024

Net income³-$333.0M in 2026+197% since 2024

Every line of the income statement as filed: the last 3 fiscal years, latest first.³

Period ending	2026-04-30	2025-04-30	2024-04-30
Net sales	$3.1B	$2.7B	$2.5B
Cost of products sold	$1.4B	$1.2B	$1.0B
Gross profit	$1.7B	$1.5B	$1.4B
Research and development expense	$448.0M	$436.0M	$437.0M
Selling, general, and administrative expense	$1.2B	$1.1B	$1.1B
Certain litigation charges, net	$18.0M	$165.0M	$0
Other operating expense (income), net	$221.0M	-$8.0M	$11.0M
Operating loss	-$190.0M	-$146.0M	-$69.0M
Other non-operating expense (income), net	-$1.0M	$1.0M	$1.0M
Loss before income taxes	-$189.0M	-$147.0M	-$70.0M
Income tax provision	$128.0M	$52.0M	$38.0M
Net loss	-$317.0M	-$198.0M	-$107.0M
Net income attributable to noncontrolling interests	-$16.0M	-$15.0M	-$5.0M
Net loss attributable to the Company	-$333.0M	-$213.0M	-$112.0M
Earnings (loss) per share, basic (usd per share)	-$1.30	-$0.84	-$0.44
Earnings (loss) per share, diluted (usd per share)	-$1.30	-$0.84	-$0.44
Basic weighted average shares outstanding (shares)	256.6M shares	252.8M shares	252.8M shares
Diluted weighted average shares outstanding (shares)	256.6M shares	252.8M shares	252.8M shares

Total assets³$4.6B in 2026+10% since 2025

Total liabilities³$1.0B in 2026+17% since 2025

Shareholders’ equity³$3.6B in 2026+6% since 2023

Cash³$298.0M in 2026+414% since 2023

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.³

Period ending	2026-04-30	2026-02-28	2025-04-30	2024-04-30	2023-04-30
Cash and cash equivalents	$298.0M		$11.0M
Accounts receivable, less allowance for credit losses of $26 and $46, respectively	$200.0M		$570.0M
Due from Medtronic	$455.0M		$0
Inventories	$341.0M		$311.0M
Other current assets	$54.0M		$48.0M
Total current assets	$1.3B		$939.0M
Property, plant, and equipment, net	$711.0M		$706.0M
Goodwill	$2.3B		$2.3B
Other intangible assets, net	$107.0M		$132.0M
Tax assets	$61.0M		$19.0M
Other assets	$147.0M		$150.0M
Total assets	$4.6B		$4.2B
Accounts payable	$163.0M		$205.0M
Accrued compensation	$163.0M		$182.0M
Accrued rebates	$45.0M		$51.0M
Total current liabilities	$702.0M		$710.0M
Other liabilities	$317.0M		$162.0M
Total liabilities	$1.0B		$871.0M
Common stock, par value $0.01, 1,000,000,000 shares authorized at April 24, 2026, 280,819,988 and no shares issued and outstanding, at April 24, 2026 and April 25, 2025, respectively	$3.0M		$0
Preferred stock, par value $0.01, 100,000,000 shares authorized, none issued and outstanding	$0		$0
Additional paid-in capital	$3.7B		$0
Retained earnings (Accumulated deficit)	-$116.0M		$0
Net parent investment	$0		$3.3B
Accumulated other comprehensive income	-$12.0M		$3.0M
Total stockholders equity	$3.6B		$3.3B	$3.4B	$3.4B
Noncontrolling interests	$0		$0
Total equity	$3.6B		$3.3B
Total liabilities and stockholders equity	$4.6B		$4.2B
Allowances for accounts receivable	$26.0M		$46.0M	$40.0M	$41.0M
Common stock, par value (in dollars per share)	$0.01		$0.01
Common stock, shares authorized (in shares)	1.0B shares		1.0B shares
Common stock, shares outstanding (in shares)	280.8M shares		0 shares	0 shares	0 shares
Common stock, shares issued (in shares)	280.8M shares		0 shares
Preferred stock, par value (in dollars per share)	$0.01		$0.01
Preferred stock, shares authorized (in shares)		100.0M shares
Preferred stock, shares issued (in shares)	0 shares		0 shares
Preferred stock, shares outstanding (in shares)	0 shares		0 shares

Period ending	2026-04-30	2026-02-28	2025-04-30	2024-04-30	2023-04-30
Cash and cash equivalents	$298.0M		$11.0M
Accounts receivable, less allowance for credit losses of $26 and $46, respectively	$200.0M		$570.0M
Due from Medtronic	$455.0M		$0
Inventories	$341.0M		$311.0M
Other current assets	$54.0M		$48.0M
Total current assets	$1.3B		$939.0M
Property, plant, and equipment, net	$711.0M		$706.0M
Goodwill	$2.3B		$2.3B
Other intangible assets, net	$107.0M		$132.0M
Tax assets	$61.0M		$19.0M
Other assets	$147.0M		$150.0M
Total assets	$4.6B		$4.2B
Accounts payable	$163.0M		$205.0M
Accrued compensation	$163.0M		$182.0M
Accrued rebates	$45.0M		$51.0M
Total current liabilities	$702.0M		$710.0M
Other liabilities	$317.0M		$162.0M
Total liabilities	$1.0B		$871.0M
Common stock, par value $0.01, 1,000,000,000 shares authorized at April 24, 2026, 280,819,988 and no shares issued and outstanding, at April 24, 2026 and April 25, 2025, respectively	$3.0M		$0
Preferred stock, par value $0.01, 100,000,000 shares authorized, none issued and outstanding	$0		$0
Additional paid-in capital	$3.7B		$0
Retained earnings (Accumulated deficit)	-$116.0M		$0
Net parent investment	$0		$3.3B
Accumulated other comprehensive income	-$12.0M		$3.0M
Total stockholders equity	$3.6B		$3.3B	$3.4B	$3.4B
Noncontrolling interests	$0		$0
Total equity	$3.6B		$3.3B
Total liabilities and stockholders equity	$4.6B		$4.2B
Allowances for accounts receivable	$26.0M		$46.0M	$40.0M	$41.0M
Common stock, par value (in dollars per share)	$0.01		$0.01
Common stock, shares authorized (in shares)	1.0B shares		1.0B shares
Common stock, shares outstanding (in shares)	280.8M shares		0 shares	0 shares	0 shares
Common stock, shares issued (in shares)	280.8M shares		0 shares
Preferred stock, par value (in dollars per share)	$0.01		$0.01
Preferred stock, shares authorized (in shares)		100.0M shares
Preferred stock, shares issued (in shares)	0 shares		0 shares
Preferred stock, shares outstanding (in shares)	0 shares		0 shares

Cash from operations³-$197.0M in 2026

Capital spending³$223.0M in 2026+51% since 2024

Free cash flow³-$420.0M in 2026+293% since 2024

Every line of the cash flow as filed: the last 3 fiscal years, latest first.³

Period ending	2026-04-30	2025-04-30	2024-04-30
Net loss	-$317.0M	-$198.0M	-$107.0M
Depreciation and amortization	$156.0M	$143.0M	$129.0M
Provision for credit losses	$28.0M	$21.0M	$22.0M
Deferred income taxes	-$54.0M	-$2.0M	$3.0M
Stock-based compensation	$46.0M	$41.0M	$38.0M
Postretirement benefit plan expense	$7.0M	$8.0M	$8.0M
Asset impairments	$84.0M	$0	$0
Other, net	$19.0M	$5.0M	$21.0M
Inventories	-$29.0M	-$19.0M	$5.0M
Blackstone funding arrangement	$157.0M	$0	$0
Other operating assets and liabilities	$66.0M	$16.0M	$30.0M
Net cash (used in) provided by operating activities	-$197.0M	$140.0M	$41.0M
Additions to property, plant, and equipment	-$223.0M	-$193.0M	-$148.0M
Purchases of investments	$0	$0	-$5.0M
Sales and maturities of investments	$0	$0	$11.0M
Other investing activities, net	-$10.0M	$0	-$14.0M
Net cash used in investing activities	-$233.0M	-$193.0M	-$157.0M
Issuance of common stock from IPO	$538.0M	$0	$0
Net transfers (to) from Parent	$407.0M	$12.0M	$112.0M
Distribution to Parent in connection with IPO	-$229.0M	$0	$0
Other financing activities, net	$0	-$2.0M	$0
Net cash provided by financing activities	$716.0M	$10.0M	$112.0M
Effect of exchange rate changes on cash and cash equivalents	$1.0M	$0	$0
Net change in cash and cash equivalents	$287.0M	-$43.0M	-$4.0M
Cash paid for income taxes	$2.0M	$0	$0
Capitalized costs in accounts payable and accrued liabilities	$23.0M	$21.0M	$28.0M

Compare MiniMed Group, Inc. with another company

Leadership

Who has led MiniMed Group, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive officerQue Dallara Mar 6, 2026 to now⁸
PresidentChristopher Eso Mar 5, 2026 to now⁹
Chief financial officerChad Spooner Mar 6, 2026 to now¹⁰

Board members and other officers (17)

OfficerAli Dianaty Mar 6, 2026 to now¹¹
OfficerCourtney Nelson Wills Mar 6, 2026 to now¹²
OfficerGillian Chandrasena Mar 6, 2026 to now¹³
OfficerJohn Gyurci Mar 6, 2026 to now¹⁴
Board memberBrian Sandstrom Mar 5, 2026 to now¹⁵
Board memberBrett A. Wall Mar 6, 2026 to now¹⁶
Board memberD. Keith Grossman Mar 6, 2026 to now¹⁷
Board memberGlenn A. Eisenberg Mar 6, 2026 to now¹⁸
Board memberKevin E. Lofton Mar 6, 2026 to now¹⁹
Board memberLaura Mauri Mar 6, 2026 to now²⁰
Board memberMatthew R. Walter Mar 6, 2026 to now²¹
Board memberQue Dallara Mar 6, 2026 to now⁸
Board memberRobert (bob) Hopkins Mar 6, 2026 to now²²
Board memberTimothy A. Wicks Mar 6, 2026 to now²³
Board memberDavid J. Endicott Jul 6, 2026 to now²⁴
Board memberLinnea Burman Jul 6, 2026 to now²⁵
Board memberScott T. Cundy Jul 6, 2026 to now²⁶

Subsidiaries and ownership

Parent company (GLEIF)

Medtronic Global Holdings S.C.A.²

Ultimate parent

MEDTRONIC PUBLIC LIMITED COMPANY²

Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Former names

MDT Sub Holdings, Inc.May 30, 2025 to May 30, 2025⁴

Timeline

Mar 6, 2026New chief executive Que Dallara becomes CEO⁸
Feb 27, 2025Founded MiniMed Group, Inc. is founded²
Feb 27, 2025Parent Directly consolidated by Medtronic Global Holdings S.C.A.²

Filings

96 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 10 major events, 55 insider forms, 1 large holders, 27 other. The latest 20:

Oct 13, 20264 EDGAR
Oct 13, 20264 EDGAR
Oct 13, 20264 EDGAR
Oct 13, 20264 EDGAR
Oct 13, 20264 EDGAR
Oct 13, 20268-K EDGAR
Oct 5, 2026EFFECT EDGAR
Oct 5, 20264 EDGAR
Oct 5, 2026424B3 EDGAR
Oct 1, 20263 EDGAR
Sep 21, 2026425 EDGAR
Sep 21, 2026425 EDGAR
Sep 14, 2026425 EDGAR
Sep 14, 2026425 EDGAR
Sep 14, 2026425 EDGAR
Sep 14, 2026425 EDGAR
Sep 14, 2026425 EDGAR
Sep 14, 2026425 EDGAR
Sep 14, 2026S-4 EDGAR
Sep 8, 202610-Q EDGAR

The 96 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

1 such filings since October 2021:

May 6, 2026SCHEDULE 13G

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 97. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Massachusetts Financial Services Co /ma/	8,334,738	$124.6M	0.0%	+1,456,278
Millennium Management LLC	3,060,615	$45.8M	0.0%	+467,181
Citadel Advisors LLC	2,865,703	$42.8M	0.0%	+14,164
Longaeva Partners L.P.	2,812,970	$42.1M	1.2%	−365,684
Sessa Capital IM, L.P.	2,000,000	$29.9M	0.5%	No change
BlackRock, Inc.	1,996,489	$29.8M	0.0%	+1,970,314
Norges Bank	1,961,002	$29.3M	0.0%	New
Rock Springs Capital Management LP	1,520,000	$22.7M	1.1%	+465,000
ExodusPoint Capital Management, LP	1,437,067	$21.5M	0.2%	+1,027,819
Fmr LLC	1,080,689	$16.2M	0.0%	−284,311
Geode Capital Management, LLC	956,024	$14.3M	0.0%	+710,093
Boston Partners	902,359	$13.5M	0.0%	+57,356
J. Goldman & Co LP	830,218	$12.4M	0.4%	New
Nuveen, LLC	539,313	$8.1M	0.0%	New
UBS Group AG	413,416	$6.2M	0.0%	+102,067
State Street Corp	403,289	$6.0M	0.0%	New
Healthcare Of Ontario Pension Plan Trust Fund	375,000	$5.6M	0.0%	−375,000
First Trust Advisors LP	366,268	$5.5M	0.0%	+267,119
Vanguard Capital Management LLC	323,325	$4.8M	0.0%	New
Adage Capital Partners Gp, L.l.c.	300,000	$4.5M	0.0%	New
Burkehill Global Management, LP	300,000	$4.5M	0.2%	No change
Readystate Asset Management LP	294,284	$4.4M	0.3%	−20,716
Neuberger Berman Group LLC	264,672	$4.0M	0.0%	New
Tudor Investment Corp Et Al	258,215	$3.9M	0.0%	+242,315
Alberta Investment Management Corp	250,000	$3.7M	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARMiniMed Group, Inc. filings on SEC EDGAR
2
GLEIFMiniMed Group, Inc. LEI record (254900MS5BIVZH51VD96)
3
SEC EDGARMiniMed Group, Inc. 10-K for fiscal 2026
4
SEC EDGARMiniMed Group, Inc. filings on SEC EDGAR
5
SEC EDGARMiniMed Group, Inc. annual report, Item 1 (Business)
6
SEC EDGARMiniMed Group, Inc. 10-Q for fiscal 2025
7
SEC EDGARMiniMed Group, Inc. 10-Q for fiscal 2026
8
SEC EDGARQue Dallara, Chief executive officer
9
SEC EDGARChristopher Eso, President
10
SEC EDGARChad Spooner, Chief financial officer
11
SEC EDGARAli Dianaty, Officer
12
SEC EDGARCourtney Nelson Wills, Officer
13
SEC EDGARGillian Chandrasena, Officer
14
SEC EDGARJohn Gyurci, Officer
15
SEC EDGARBrian Sandstrom, Board member
16
SEC EDGARBrett A. Wall, Board member
17
SEC EDGARD. Keith Grossman, Board member
18
SEC EDGARGlenn A. Eisenberg, Board member
19
SEC EDGARKevin E. Lofton, Board member
20
SEC EDGARLaura Mauri, Board member
21
SEC EDGARMatthew R. Walter, Board member
22
SEC EDGARRobert (bob) Hopkins, Board member
23
SEC EDGARTimothy A. Wicks, Board member
24
SEC EDGARDavid J. Endicott, Board member
25
SEC EDGARLinnea Burman, Board member
26
SEC EDGARScott T. Cundy, Board member